Status:

TERMINATED

Down Syndrome Speech Intelligibility Diagnostic Treatment Study

Lead Sponsor:

University of Wisconsin, Madison

Collaborating Sponsors:

Office of the Vice Chancellor for Research and Graduate Education

Wisconsin Alumni Research Foundation

Conditions:

Down Syndrome

Eligibility:

MALE

7-16 years

Phase:

NA

Brief Summary

The 'Down syndrome speech intelligibility diagnostic treatment study' is a pilot clinical intervention study assessing the efficacy of an integrative speech treatment approach for individuals with Dow...

Detailed Description

The 'Down syndrome speech intelligibility diagnostic treatment study' is a pilot clinical intervention study assessing the efficacy of an integrative speech treatment approach for individuals with Dow...

Eligibility Criteria

Inclusion

  • Males with a diagnosis of Down syndrome between the ages of 7 and 16 years
  • Primary language is English
  • Interested in improving their speech intelligibility.
  • All participants must consent/assent to participate. As this is a multiple single subject design, services are available to all motivated participants who are willing to commit to the time/durations described in the diagnostic treatment.

Exclusion

  • Primary language is not American English
  • Do not have a diagnosis of Down syndrome
  • Female
  • Ages birth-6 and 17 years or older
  • Individuals who have a co-occurring diagnosis that affects communication abilities \[e.g., diagnosed as deaf with cochlear implants, Autism, only use an alternative/augmentative communication (AAC) device to communicate\],
  • Severe hearing loss which will limit their ability to participate in the treatment
  • Individuals with a known mild or moderate hearing loss or current speech- language therapy services will not be excluded, but this information will be requested in the Parent Questionnaire. In addition, access to their current individualized education program (IEP) will be requested.

Key Trial Info

Start Date :

September 5 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 28 2020

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT04059354

Start Date

September 5 2019

End Date

February 28 2020

Last Update

February 7 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Waisman Center, 1500 Highland Avenue

Madison, Wisconsin, United States, 53705